Patents Assigned to AstraZeneca
  • CHEMICAL PROCESS
    Publication number: 20100094010
    Abstract: Processes for preparing compounds of Formula I and IV are described.
    Type: Application
    Filed: October 16, 2009
    Publication date: April 15, 2010
    Applicant: AstraZeneca AB
    Inventors: Margaret Anne Butlin, Roger John Butlin, Philip John Hogan, Andreas Meudt
  • Novel Heteroaryl Substituted Imidazo [1,2-A] Pyridine Derivatives
    Publication number: 20100092385
    Abstract: The present invention relates to novel heteroaryl substituted imidazopyridine derivatives, precursors thereof, and therapeutic uses of such compounds, having the structural formula (Ia) and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel heteroaryl substituted imidazopyridine derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents.
    Type: Application
    Filed: January 21, 2008
    Publication date: April 15, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Michaela Vallin, Jonas Malmstrom, David Pyring, Can Slivo, David Wensbo
  • THERAPEUTIC AGENTS 414
    Publication number: 20100093757
    Abstract: A compound of Formula (I): is useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK or GK), leading to a decreased glucose threshold for insulin secretion.
    Type: Application
    Filed: August 4, 2009
    Publication date: April 15, 2010
    Applicant: AstraZeneca AB
    Inventors: Stuart Norman Lile BENNETT, Roger John Butlin, Leonie Campbell, Robert Darren Morse Davies, Graeme Richard Robb, Rolf Peter Walker, Michael James Waring, Helen Claire Pointon, Mikael Dan Brink, Jonas Rickard Fägerhag, Ulrik Jurva, Volker Schnecke, Anette Marie Svensson Henriksson, Christer Ralf Westerlund, Peter Gustaf Bonn
  • Salts 668
    Publication number: 20100093813
    Abstract: A pharmaceutically acceptable salt of N-[2-(Diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-naphthyl)ethoxy]propan amide provided it is not the dihydrobromide or dihydrochloride salt; and the use of such a compound as a medicament (for example in the treatment of respiratory diseases (such as asthma or COPD).
    Type: Application
    Filed: February 6, 2008
    Publication date: April 15, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Robert Whittock, Jane Withnall
  • 4-oxoquinazolin-3-yl benzamide derivatives for the treatment of cytokine diseases
    Patent number: 7696215
    Abstract: The invention concerns a compound of the Formula (I) wherein m is 1-2 and each R1 is a group such as cyano, halogeno, trifluoromethyl heterocyclyl and heterocyclyloxy; R2 is trifluoromethyl or (1-6C)alkyl; R3 is hydrogen or halogeno; and R4 is isoxazolyl; or pharmaceutically-acceptable salts thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.
    Type: Grant
    Filed: February 23, 2006
    Date of Patent: April 13, 2010
    Assignee: AstraZeneca AB
    Inventors: Ian Alun Nash, Jonathan Erle Finlayson, Caroline Rachel Thompson
  • Crystalline compound
    Patent number: 7696191
    Abstract: A novel crystalline form of 3-{[5-(azetidin-1-ylcarbonyl)pyrazin-2-yl]oxy}-5-[(1-methylethyl)oxy]-N-1H-pyrazol-3-ylbenzamide is described in the specification. This compound is a glucokinase (GLK or GK) activator and useful as a pharmaceutical agent in the treatment or prevention of a disease or medical condition mediated through GLK, leading to a decreased glucose threshold for insulin secretion. Processes for the manufacture of the crystalline form, pharmaceutical compositions comprising the crystalline form and the use of the crystalline form in medical treatment are also described.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: April 13, 2010
    Assignee: AstraZeneca AB
    Inventors: James McCabe, Gary Peter Tomkinson
  • Quinazoline derivatives for the treatment of tumours
    Patent number: 7696214
    Abstract: The invention concerns quinazoline derivatives of Formula (I) wherein each of Q1, Z, m, R1, R2, R3 and Q2 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumor disease.
    Type: Grant
    Filed: November 21, 2005
    Date of Patent: April 13, 2010
    Assignee: AstraZeneca AB
    Inventors: Laurent François André Hennequin, Patrick Ple
  • PHARMACEUTICAL RELATIONAL DATABASE
    Publication number: 20100088108
    Abstract: Apparatus and methods for providing a pharmaceutical relational database are provided. A computer readable medium comprising a database according to the invention may include a first set of data relating to pharmacy eligibility for a medication. The database may also include a second set of data relating to health plan support for the medication, a third set of data relating to patient medication history; and a fourth set of data relating to special offers provided by a pharmaceutical company for the medication.
    Type: Application
    Filed: October 8, 2008
    Publication date: April 8, 2010
    Applicant: AstraZeneca AB
    Inventor: Paulo Machado
  • Chemical compounds
    Patent number: 7691867
    Abstract: Quinazoline derivatives of formula (I); for use in the treatment of proliferative diseases such as cancer and in the preparation of medicaments for use in the treatment of proliferative diseases, and to process for their preparation, as well as pharmaceutical compositions containing them as active ingredient.
    Type: Grant
    Filed: April 14, 2004
    Date of Patent: April 6, 2010
    Assignee: AstraZeneca AB
    Inventors: Nicola Murdoch Heron, Georges Rene Pasquet, Andrew Austen Mortlock, Frederic Henri Jung
  • Imidazopyridine compounds, processes for their preparation and therapeutic uses thereof
    Patent number: 7691875
    Abstract: The present invention relates to imidazopyridine derivatives of the Formula I and, therapeutically acceptable salts thereof which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the treatment of gastrointestinal inflammatory diseases. In further aspects, the invention relates to the compound of the invention for use in therapy; to processes for preparation of such new compound; to pharmaceutical compositions containing the compound of the invention, or a therapeutically acceptable salt thereof, as active ingredient; and to the use of the compound of the invention in the manufacture of medicaments for the medical use indicated above.
    Type: Grant
    Filed: June 23, 2004
    Date of Patent: April 6, 2010
    Assignee: AstraZeneca AB
    Inventor: Peter Nordberg
  • Tetrazole compounds and their use as metabotropic glutamate receptor antagonists
    Patent number: 7691892
    Abstract: The present invention relates to new compounds of formula I, wherein P, Q, X1, X2, X3, X4, R1, R2, m and p, are as defined as in formula I, or, salts, solvates or solvated salts thereof, processes for their preparation and new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.
    Type: Grant
    Filed: February 18, 2005
    Date of Patent: April 6, 2010
    Assignee: AstraZeneca AB
    Inventors: Martin Johansson, Alexander Minidis, Karin Staaf, David Wensbo, Donald McLeod, Louise Edwards, Methvin Isaac, Anne O'Brien, Abdelmalik Slassi, Tao Xin, Tomislav Stefanac
  • Novel 1-Benzyl-4-Piperidinamines that are Useful in the Treatment of COPD and Asthma
    Publication number: 20100081692
    Abstract: The invention provides 1-benzyl-4-piperidinamines of the general formula (I), processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are useful in the treatment of respiratory diseases such as chronic obstructive pulmonary disease and asthma. The compounds are inhibitors of the CCR1 receptor.
    Type: Application
    Filed: October 31, 2006
    Publication date: April 1, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Martin Hemmerling, Nafizal Hossain, Svetlana Ivanova, Tesfaledet Mussie, Igor Shamovsky, Asa Sjoholm Timen
  • Antibodies directed to monocyte chemo-attractant protein-1 (MCP-1) and uses thereof
    Patent number: 7687606
    Abstract: Embodiments of the invention described herein relate to antibodies directed to the antigen monocyte chemo-attractant protein-1 (MCP-1) and uses of such antibodies. In particular, in accordance with some embodiments, there are provided fully human monoclonal antibodies directed to the antigen MCP-1. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: March 30, 2010
    Assignee: AstraZeneca AB
    Inventors: Jean M. Gudas, Mary Haak-Frendscho, Orit Foord, Meina L. Liang, Kiran Ahluwalia, Sunil Bhakta
  • Substituted 3-sulfur indoles
    Patent number: 7687535
    Abstract: The present invention relates to substituted indoles useful as pharmaceutical compounds for treating respiratory disorders.
    Type: Grant
    Filed: May 25, 2004
    Date of Patent: March 30, 2010
    Assignee: AstraZeneca AB
    Inventors: Roger Bonnert, Rukhsana Mohammed, Mark Robert Dickinson
  • N-PHENYL-4-PYRIDIN-2-YL-BENZAMIDE DERIVATIVES AS HISTONE DEACYLASE (HDAC) INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20100075942
    Abstract: The invention concerns benzamide derivatives of Formula (I) wherein R1a, R1b, R1c, R2, R3, R4, W, m and n have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of histone deacetylase (HDAC).
    Type: Application
    Filed: January 12, 2006
    Publication date: March 25, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Keith Hopkinson Gibson, Elaine Sophie, Elizabeth Stokes, Michael James Waring, David Michael Andrews, Zbigniew Stanley Matusiak, Mark Maybury, Craig Anthony Roberts
  • Novel Compounds Having Selective Inhibiting Effect at GSK3
    Publication number: 20100075989
    Abstract: Compounds of formula I wherein Z, X, Y, ring P, ring Q, R, R3, R4, n and m are as defined in the specification, as a free base or a pharmaceutically acceptable salt, solvate or solvate of a salt; processes for their preparation and new intermediates used therein, pharmaceutical formulations containing said compounds, and the use of said compounds in therapy.
    Type: Application
    Filed: August 21, 2009
    Publication date: March 25, 2010
    Applicant: AstraZeneca AB
    Inventors: Stefan Berg, Sven Hellberg, Peter Soderman
  • 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (GSK-3)
    Patent number: 7683067
    Abstract: Compounds of formula Ia or Ib wherein P; R1; R2; m; and n are as defined in the application, salts thereof, processed for their preparation, new intermediates used therein, pharmaceutical formulations containing said compounds and the use of said compounds in therapy.
    Type: Grant
    Filed: September 21, 2004
    Date of Patent: March 23, 2010
    Assignee: AstraZeneca AB
    Inventors: Stefan Berg, Sven Hellberg
  • Method for the synthesis of a benzimidazole compound
    Patent number: 7683178
    Abstract: A process for the manufacture of omeprazole or esomeprazole from pyrmethyl alcohol via pyrmethyl chloride and pyrmetazole characterized in that the whole reaction sequence is carried out without any isolation or purification of intermediates. Further, the reaction is carried out in a solvent system common for the whole reaction sequence and inert to the reactants formed during the process and used in the process and comprises a water immiscible organic solvent and a specified amount of water.
    Type: Grant
    Filed: May 16, 2007
    Date of Patent: March 23, 2010
    Assignee: AstraZeneca AB
    Inventor: Anders Gustavsson
  • Process for Preparation of a Stable Dispersion of Solid Amorphous Submicron Particles in an Aqueous Medium
    Publication number: 20100068287
    Abstract: The invention relates to a process for the preparation of a stable dispersion of particles, particularly sub-micron particles in an aqueous medium and to a stable dispersion of particles in a liquid medium. The sub-micron dispersion provided exhibit reduced or substantially no particle growth during storage and reduced crystallisation rate of the substantially water insoluble active compound.
    Type: Application
    Filed: February 8, 2008
    Publication date: March 18, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Lennart Lindfors, Urban Skantze
  • New Pyridine Analogues III
    Publication number: 20100069350
    Abstract: The present invention relates to certain new pyridin analogues of Formula (I), to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.
    Type: Application
    Filed: July 2, 2007
    Publication date: March 18, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Thomas Antonsson, Peter Bach, David Brown, Ruth Bylund, Fabrizio Giordanetto, Lotta Jakobsson, Johan Johansson